Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT678
- Development stage
- Phase 2
- Lead developer
- Diapin Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DT678 is a novel, orally active P2Y12 receptor antagonist being developed by Beijing SL Pharmaceutical Co., Ltd. for the treatment and prevention of atherothrombotic events. It is primarily being investigated for use in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), particularly those undergoing percutaneous coronary intervention (PCI). The drug works by selectively inhibiting the P2Y12 subtype of adenosine diphosphate (ADP) receptors on the platelet surface, thereby preventing platelet activation and aggregation. DT678 is currently in Phase 2 clinical development, where it is being evaluated for its efficacy and safety compared to standard antiplatelet therapies like clopidogrel.
- Other names
- ClopNPT
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on DT678.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DT678.